Interventional Treatment of Hypertension: A New Paradigm
Hypertension is thought to contribute to more than 7 million deaths worldwide each year and contributes to the development of atherosclerotic lesions that lead to myocardial infarction and stroke. While lifestyle modifications (diet, exercise, weight loss) and pharmacotherapy have been proven to be effective in the treatment of hypertension, as many as half of patients have uncontrolled BP and remain at risk for elevated cardiovascular morbidity and mortality. The main physiologic targets for interventional treatment include alteration of blood flow to the kidney, activation of the carotid baroreflex system, and modification of the renal sympathetic nervous system. The results of prior studies and new studies of interventional treatments of resistant hypertension are covered in this review.
KeywordsHypertension Resistant hypertension Baroreceptor activation therapy Renal artery stenosis Renal sympathetic denervation
Duke University is a clinical site involved in enrollment of patients in SYMPLICITY HTN-3. As such, Duke receives research money to participate. All 3 of the authors are site investigators but do not receive salary or other compensation for this project.
Conflict of Interest
W.S. Jones declares that he has no conflict of interest.
S. Vemulapalli has received grant support from Medtronic for a peripheral vascular disease fellowship grant. He has also received travel/accommodations expenses covered or reimbursed from Medtronic for travel costs for SYMPLICITY HTN-3 investigators meeting.
M.R. Patel has been a consultant for Genzyme, Baxter, Jensen, and Bayer. He has received grant support from AstraZeneca, Johnson & Johnson, and Maquet.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation. 2011;123:2434–506.PubMedCrossRefGoogle Scholar
- 3.Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761–88.PubMedCrossRefGoogle Scholar
- 5.Global Health Risks, World Health Organization, 2009. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf. Accessed 7 Nov 2012.
- 6.Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.PubMedCrossRefGoogle Scholar
- 9.• Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42. This community cohort study is a nice descriptive analysis of resistant hypertension and outcomes in these patients.PubMedCrossRefGoogle Scholar
- 16.• Kumbhani DJ, Bavry AA, Harvey JE, de Souza R, Scarpioni R, Bhatt DL, et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J. 2011;161:622–30. This is the most updated meta-analysis on treatment of hypertension with renal artery revascularization.PubMedCrossRefGoogle Scholar
- 17.• Jaff MR, Bates M, Sullivan T, Popma J, Gao X, Zaugg M, et al. Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheter Cardiovasc Interv. 2012;80:343–50. A single-arm study of renal artery stenting in selected population of uncontrolled hypertensive patients.PubMedCrossRefGoogle Scholar
- 18.Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): a Collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol. 2006;47:e1–e192.CrossRefGoogle Scholar
- 24.•• Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:765–73. The largest study of baroreflex activation therapy published to date.PubMedCrossRefGoogle Scholar
- 31.• Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7. The first study to show that renal sympathetic denervation is associated with long-term blood pressure reduction. Google Scholar
- 32.•• Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903–9. This study reported the safety and effectiveness of renal sympathetic denervation when compared with control in resistant hypertension. Google Scholar
- 38.Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, et al. Effects of Renal Sympathetic Denervation on Heart Rate and Atrioventricular Conduction in Patients with Resistant Hypertension. Int J Cardiol 2012 [epub ahead of print].Google Scholar
- 42.Ormiston J, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, et al. First report of the 6-month first in human results of the OneShot renal denervation system: the RHAS Study [Abstract TCT-212]. Presented at Transcatheter Cardiovascular Therapeutics Conference. Miami, Florida, USA; October 22–26, 2012.Google Scholar
- 43.Worthley S, Tsioufis C, Worthley M, Sinhal A, Chew D, Meredith I, et al. Safety and efficacy of a novel multi-electrode renal denervation catheter in resistant hypertension: 3 month data from the EnligHTN I Trial. [Abstract TCT-213]. Presented at Transcatheter Cardiovascular Therapeutics Conference. Miami, Florida, USA; October 22–26, 2012.Google Scholar